Skip to main content

Staxyn Side Effects

Generic name: vardenafil

Medically reviewed by Drugs.com. Last updated on Apr 26, 2023.

Note: This document contains side effect information about vardenafil. Some dosage forms listed on this page may not apply to the brand name Staxyn.

Applies to vardenafil: oral tablet, oral tablet disintegrating.

Serious side effects of Staxyn

Along with its needed effects, vardenafil (the active ingredient contained in Staxyn) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking vardenafil:

Less common

Incidence not known

Other side effects of Staxyn

Some side effects of vardenafil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to vardenafil: oral tablet, oral tablet disintegrating.

General

The most commonly reported adverse reaction is headache.[Ref]

Cardiovascular

Very common (10% or more): Flushing (11%)

Common (1% to 10%): Palpitation, tachycardia, angina pectoris, myocardial infarction, ventricular tachyarrhythmias, hypotension

Rare (less than 0.1%): Hypertension

Postmarketing reports: Serious cerebrovascular hemorrhage, sudden cardiac death, transient ischemic attack, unstable angina and ventricular arrhythmia have been reported in temporal association with another medicinal product in this class.[Ref]

Nervous system

Very common (10% or more): Headache (15%)

Common (1% to 10%): Dizziness, paresthesia and dysesthesia, somnolence, sleep disorder, syncope, amnesia, seizure

Postmarketing reports: Seizure, seizure recurrence, transient global amnesia[Ref]

Dermatologic

Common (1% to 10%): Erythema, rash, angioedema, allergic edema

Rare (less than 0.1%): Photosensitivity reaction[Ref]

Gastrointestinal

Common (1% to 10%): Dyspepsia, nausea, gastrointestinal and abdominal pain, dry mouth, diarrhea, gastroesophageal reflux disease, gastritis, vomiting[Ref]

Genitourinary

Uncommon (0.1% to 1%): Increase in erection

Rare (less than 0.1%): Priapism

Postmarketing reports: Penile hemorrhage, hematospermia[Ref]

Hepatic

Common (1% to 10%): Increase in transaminases

Rare (less than 0.1%) Increase in gamma-glutamyl-transferase[Ref]

Hypersensitivity

Common (1% to 10%): Allergic reactions

Musculoskeletal

Common (1% to 10%): Back pain, increase in creatine phosphokinase (CPK), increased muscle tone and cramping, myalgia[Ref]

Ocular

Common (1% to 10%): Visual disturbance, ocular hyperemia, visual color distortions, eye pain and eye discomfort, photophobia, increase in intraocular pressure, conjunctivitis

Rare (less than 0.1%): Increased lacrimation

Postmarketing reports: Non-arteritic anterior ischemic optic neuropathy (NAION), visual disturbances including vision loss (temporary or permanent), such as visual field defect, retinal vein occlusion, and reduced visual acuity.[Ref]

Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including vardenafil.[Ref]

Other

Common (1% to 10%): Accidental injury, flu syndrome, tinnitus, vertigo, chest pain, feeling unwell

Postmarketing reports: Cases of sudden decrease or loss of hearing in temporal association with the use of PDE5 inhibitors, including this drug[Ref]

Renal

Common (1% to 10%): Increased creatinine kinase

Postmarketing reports: Hematuria[Ref]

Respiratory

Common (1% to 10%): Rhinitis, sinusitis, dyspnea, sinus congestion, nasal congestion

Rare (less than 0.1%): Epistaxis[Ref]

References

1. Product Information. Levitra (vardenafil). Bayer. 2003.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

4. Product Information. Staxyn (vardenafil). Merck & Co., Inc. 2014.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.